The U.S. Food and Drug Administration (FDA) recently approved the use of a prescription drug, Latisse (bimatoprost ophthalmic solution, 0.03%), to help lengthen, thicken and darken eyelashes. It has the same active ingredient (called a prostaglandin analog) as a drug called Lumigan used for treating glaucoma.
It was discovered that some people using Lumigan to treat their glaucoma found they had increased length, darkening and/ thickening of their eyelashes. This desirable effect led to the use of this drug for cosmetic purposes. However, there are other, undesirable side effects of bimatoprost ophthalmic solution such as eye redness, irritation and darkening of the skin of the eyelids (all of which can be reversed once the drug is no longer taken). Darkening of the iris (the colored portion of the eye) has also been reported, and this side effect cannot be reversed.
If you have an eye condition, such as glaucoma, macular edema or eye inflammation, or if you have any questions or concerns about your eye health and Latisse, see your ophthalmologist, who can evaluate you to make sure you are a good candidate for Latisse as well as prescribe this drug for you. Also, to reduce the risk of side effects from using Latisse, closely follow the instructions for using the drug.
Some important considerations to remember:
Read the American Academy of Ophthalmology’s position statement on Latisse PDF (72K).
Copyright July 19th, 2011 ® American Academy of Opthalmology